Breaking News, Collaborations & Alliances

Halozyme, BioAtla In Active Biologics Research Pact

Halozyme Therapeutics, Inc. has signed an exclusive, worldwide, contract research collaboration with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatol

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Halozyme Therapeutics, Inc. has signed an exclusive, worldwide, contract research collaboration with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation. During the initial three-year term of the agreement, Halozyme will receive exclusive worldwide commercial rights from BioAtla to conditionally active biologics (CABs) that result from the agreement. The program aims to g...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters